Acute but not chronic activation of brain glucagon-like peptide-1 receptors enhances glucose-stimulated insulin secretion in mice

Diabetes, Obesity and Metabolism

Volumn 17, Issue 8, 2015, Pages 789-799

  Tuduri E ^a,b   Beiroa, D ^a,b   Porteiro, B ^a,b   Lopez M ^a,b   Dieguez C ^a,b   Nogueiras, R ^a,b  

^a Universidade de Santiago de Compostela and Instituto de Investigación Sanitaria de Santiago de Compostela   (Spain)

^b Instituto de Salud Carlos III   (Spain)

Author keywords

Central nervous system; Exendin 9; Glucagon like peptide 1; Glucose metabolism; Islets; cells

Indexed keywords

BRAIN RECEPTOR; EXENDIN (9-39); GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR ANTAGONIST; GLUCOSE; HORMONE RECEPTOR AFFECTING AGENT; UNCLASSIFIED DRUG; GLUCOSE BLOOD LEVEL; INCRETIN; INSULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL FUNCTION; CENTRAL NERVOUS SYSTEM; CHRONIC DRUG ADMINISTRATION; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG INFUSION; EX VIVO STUDY; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE; GLUCOSE TOLERANCE TEST; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; LEAN BODY WEIGHT; LIPID DIET; MALE; MOUSE; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; RECEPTOR BLOCKING; RODENT; ANALYSIS; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN; C57BL MOUSE; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; METABOLISM; SECRETION (PROCESS);

ANIMALS; BLOOD GLUCOSE; BRAIN; DIET, HIGH-FAT; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; GLUCOSE; HOMEOSTASIS; INCRETINS; INFUSIONS, INTRAVENTRICULAR; INSULIN; INSULIN-SECRETING CELLS; MALE; MICE; MICE, INBRED C57BL;

EID: 84937815481     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12488     Document Type: Article

References (47)

1. D'Alessio DA, Vogel R, Prigeon R etal. Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons. J Clin Invest 1996; 97: 133-138.
2. Kolligs F, Fehmann HC, Goke R, Goke B. Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide. Diabetes 1995; 44: 16-19.
3. Scrocchi LA, Brown TJ, MaClusky N etal. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat Med 1996; 2: 1254-1258.
4. Lamont BJ, Li Y, Kwan E etal. Pancreatic GLP-1 receptor activation is sufficient for incretin control of glucose metabolism in mice. J Clin Invest 2012; 122: 388-402.
5. Sisley S, Gutierrez-Aguilar R, Scott M etal. Neuronal GLP1R mediates liraglutide's anorectic but not glucose-lowering effect. J Clin Invest 2014; 124: 2456-2463.
6. Smith EP, An Z, Wagner C etal. The role of beta cell glucagon-like peptide-1 signaling in glucose regulation and response to diabetes drugs. Cell Metab 2014; 19: 1050-1057.
7. Schirra J, Katschinski M, Weidmann C etal. Gastric emptying and release of incretin hormones after glucose ingestion in humans. J Clin Invest 1996; 97: 92-103.
8. Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 1987; 2: 1300-1304.
9. Mojsov S, Weir GC, Habener JF. Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J Clin Invest 1987; 79: 616-619.
10. Schirra J, Nicolaus M, Roggel R etal. Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans. Gut 2006; 55: 243-251.
11. Willms B, Werner J, Holst JJ etal. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab 1996; 81: 327-332.
12. Prigeon RL, Quddusi S, Paty B, D'Alessio DA. Suppression of glucose production by GLP-1 independent of islet hormones: a novel extrapancreatic effect. Am J Physiol Endocrinol Metab 2003; 285: E701-707.
13. Alcantara AI, Morales M, Delgado E etal. Exendin-4 agonist and exendin(9-39)amide antagonist of the GLP-1(7-36)amide effects in liver and muscle. Arch Biochem Biophys 1997; 341: 1-7.
14. Redondo A, Trigo MV, Acitores A, Valverde I, Villanueva-Penacarrillo ML. Cell signalling of the GLP-1 action in rat liver. Mol Cell Endocrinol 2003; 204: 43-50.
15. Nauck MA, Heimesaat MM, Orskov C etal. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993; 91: 301-307.
16. Riedel MJ, Kieffer TJ. Treatment of diabetes with glucagon-like peptide-1 gene therapy. Expert Opin Biol Ther 2010; 10: 1681-1692.
17. Jin SL, Han VK, Simmons JG etal. Distribution of glucagonlike peptide I (GLP-I), glucagon, and glicentin in the rat brain: an immunocytochemical study. J Comp Neurol 1988; 271: 519-532.
18. Han VK, Hynes MA, Jin C etal. Cellular localization of proglucagon/glucagon-like peptide I messenger RNAs in rat brain. J Neurosci Res 1986; 16: 97-107.
19. Sandoval DA, Bagnol D, Woods SC, D'Alessio DA, Seeley RJ. Arcuate glucagon-like peptide 1 receptors regulate glucose homeostasis but not food intake. Diabetes 2008; 57: 2046-2054.
20. Larsen PJ, Tang-Christensen M, Jessop DS. Central administration of glucagon-like peptide-1 activates hypothalamic neuroendocrine neurons in the rat. Endocrinology 1997; 138: 4445-4455.
21. Goke R, Larsen PJ, Mikkelsen JD, Sheikh SP. Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites. Eur J Neurosci 1995; 7: 2294-2300.
22. Shimizu I, Hirota M, Ohboshi C, Shima K. Identification and localization of glucagon-like peptide-1 and its receptor in rat brain. Endocrinology 1987; 121: 1076-1082.
23. McMahon LR, Wellman PJ. PVN infusion of GLP-1-(7-36) amide suppresses feeding but does not induce aversion or alter locomotion in rats. Am J Physiol 1998; 274: R23-29.
24. Grill HJ, Carmody JS, Amanda Sadacca L, Williams DL, Kaplan JM. Attenuation of lipopolysaccharide anorexia by antagonism of caudal brain stem but not forebrain GLP-1-R. Am J Physiol Regul Integr Comp Physiol 2004; 287: R1190-1193.
25. Beiroa D, Imbernon M, Gallego R etal. GLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK. Diabetes 2014; 63: 3346-3358.
26. Knauf C, Cani PD, Ait-Belgnaoui A etal. Brain glucagon-like peptide 1 signaling controls the onset of high-fat diet-induced insulin resistance and reduces energy expenditure. Endocrinology 2008; 149: 4768-4777.
27. Knauf C, Cani PD, Perrin C etal. Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage. J Clin Invest 2005; 115: 3554-3563.
28. Cabou C, Campistron G, Marsollier N etal. Brain glucagon-like peptide-1 regulates arterial blood flow, heart rate, and insulin sensitivity. Diabetes 2008; 57: 2577-2287.
29. Imbernon M, Beiroa D, Vazquez MJ etal. Central melanin-concentrating hormone influences liver and adipose metabolism via specific hypothalamic nuclei and efferent autonomic/JNK1 pathways. Gastroenterology 2013; 144: 636-649.
30. Romero-Pico A, Vazquez MJ, Gonzalez-Touceda D etal. Hypothalamic kappa-opioid receptor modulates the orexigenic effect of ghrelin. Neuropsychopharmacology 2013; 38: 1296-1307.
31. Czyzyk TA, Romero-Pico A, Pintar J etal. Mice lacking delta-opioid receptors resist the development of diet-induced obesity. FASEB J 2012; 26: 3483-3492.
32. Tudurí E, Denroche HC, Kara JA etal. Partial ablation of leptin signaling in mouse pancreatic alpha-cells does not alter either glucose or lipid homeostasis. Am J Physiol Endocrinol Metab 2014; 306: E748-755.
33. Tudurí E, Bruin JE, Denroche HC etal. Impaired Ca(2+) signaling in beta-cells lacking leptin receptors by Cre-loxP recombination. PLoS One 2013; 8: e71075.
34. Kastin AJ, Akerstrom V, Pan W. Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier. J Mol Neurosci 2002; 18: 7-14.
35. Ahren B, Thomaseth K, Pacini G. Reduced insulin clearance contributes to the increased insulin levels after administration of glucagon-like peptide 1 in mice. Diabetologia 2005; 48: 2140-2146.
36. Nogueiras R, Perez-Tilve D, Veyrat-Durebex C etal. Direct control of peripheral lipid deposition by CNS GLP-1 receptor signaling is mediated by the sympathetic nervous system and blunted in diet-induced obesity. J Neurosci 2009; 29: 5916-5925.
37. Lockie SH, Heppner KM, Chaudhary N etal. Direct control of brown adipose tissue thermogenesis by central nervous system glucagon-like peptide-1 receptor signaling. Diabetes 2012; 61: 2753-2762.
38. Turton MD, O'Shea D, Gunn I etal. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 1996; 379: 69-72.
39. Winzell MS, Ahren B. The high-fat diet-fed mouse: a model for studying mechanisms and treatment of impaired glucose tolerance and type 2 diabetes. Diabetes 2004; 53(Suppl. 3): S215-219.
40. Kieffer TJ, Habener JF. The glucagon-like peptides. Endocr Rev 1999; 20: 876-913.
41. Vilsboll T, Agerso H, Krarup T, Holst JJ. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab 2003; 88: 220-224.
42. Barrera JG, Jones KR, Herman JP etal. Hyperphagia and increased fat accumulation in two models of chronic CNS glucagon-like peptide-1 loss of function. J Neurosci 2011; 31: 3904-3913.
43. Sandoval D. CNS GLP-1 regulation of peripheral glucose homeostasis. Physiol Behav 2008; 94: 670-674.
44. Burmeister MA, Ferre T, Ayala JE, King EM, Holt RM. Acute activation of central GLP-1 receptors enhances hepatic insulin action and insulin secretion in high-fat-fed, insulin resistant mice. Am J Physiol Endocrinol Metab 2012; 302: E334-343.
45. Meeran K, O'Shea D, Edwards CM etal. Repeated intracerebroventricular administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters body weight in the rat. Endocrinology 1999; 140: 244-250.
46. Tang-Christensen M, Larsen PJ, Goke R etal. Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. Am J Physiol 1996; 271(Pt 2): R848-856.
47. Theander-Carrillo C, Wiedmer P, Cettour-Rose P etal. Ghrelin action in the brain controls adipocyte metabolism. J Clin Invest 2006; 116: 1983-1993.